Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
- PMID: 8968107
Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
Abstract
The in vivo production of interleukin (IL)-10, IL-6, IL-2, and tumor necrosis factor (TNF)-alpha in tumor samples was investigated by immunohistochemistry in 54 non-Hodgkin's lymphomas (NHLs). Respectively, 55, 89, 23, and 29% of tumor samples were found positive for IL-10, IL-6, IL-2, and TNF-alpha expression by immunohistochemistry. Using reverse transcription-PCR, the mRNA of IL-10 and IL-6 were detectable in all samples tested and in 90 and 34% of the samples for TNF-alpha and IL-2, respectively. In 13 patients, fresh tumor tissue was available for B NHL cell purification with Dynabeads. IL-10, IL-6, IL-2, and TNF-alpha were detectable in the supernatant of 38, 100, 0, and 23% of purified tumor cell preparations (PTCPs), respectively. All patients with detectable IL-10 in culture had increased serum IL-10. IL-6 production by tumor cells and serum IL-6 levels were also found to be highly correlated (P < 0.0001). This suggests that tumor cells are a major source of serum IL-1O and IL-6 in these patients. Exogenous IL-10, IL-6, IL-2, and TNF-alpha significantly enhanced the [3H]thymidine uptake in 13 of 13 (100%), 5 of 13 (38%), 9 of 13 (69%), and 2 of 10 (20%) PTCPs costimulated with anti-CD40, respectively. IL-2, IL-6, and TNF-alpha synergized with IL-10 in 54, 23, and 30% of PTCPs. The combination of IL-10, IL-2, and IL-6 induced the maximal level of proliferation in 12 (92%) of 13 PTCPs. CD40 ligand mRNA expression was also detectable in vivo using reverse transcription-PCR in 28 of the 29 (97%) tumor samples tested, including 11 of those tested for [3H]thymidine incorporation. These results show that IL-1O, IL-6, IL-2, and TNF-alpha are produced in NHL tumors and may cooperate in vivo to increase NHL cell proliferation.
Similar articles
-
Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response.J Immunol. 1995 Jan 15;154(2):718-29. J Immunol. 1995. PMID: 7814878
-
Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.Cancer Res. 1993 May 1;53(9):2118-22. Cancer Res. 1993. PMID: 8481913
-
Cell dynamics and expression of tumor necrosis factor (TNF)-alpha, interleukin-6, and TNF receptors in angioimmunoblastic lymphadenopathy-type T cell lymphoma.Exp Mol Pathol. 2000 Apr;68(2):85-94. doi: 10.1006/exmp.1999.2297. Exp Mol Pathol. 2000. PMID: 10716912
-
Interleukin-10 in non-Hodgkin's lymphoma.Leuk Lymphoma. 1997 Jul;26(3-4):251-9. doi: 10.3109/10428199709051774. Leuk Lymphoma. 1997. PMID: 9322887 Review.
-
Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma.Leuk Lymphoma. 1998 Mar;29(1-2):71-9. doi: 10.3109/10428199809058383. Leuk Lymphoma. 1998. PMID: 9638977 Review.
Cited by
-
The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.Int J Hematol. 2003 Apr;77(3):286-94. doi: 10.1007/BF02983788. Int J Hematol. 2003. PMID: 12731674
-
Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells.Cancer Sci. 2005 Dec;96(12):897-902. doi: 10.1111/j.1349-7006.2005.00124.x. Cancer Sci. 2005. PMID: 16367910 Free PMC article.
-
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Front Immunol. 2018 Jan 17;8:1936. doi: 10.3389/fimmu.2017.01936. eCollection 2017. Front Immunol. 2018. PMID: 29387053 Free PMC article. Review.
-
The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.Yonsei Med J. 2014 Nov;55(6):1568-75. doi: 10.3349/ymj.2014.55.6.1568. Yonsei Med J. 2014. PMID: 25323893 Free PMC article.
-
The Immunology of DLBCL.Cancers (Basel). 2023 Jan 29;15(3):835. doi: 10.3390/cancers15030835. Cancers (Basel). 2023. PMID: 36765793 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials